Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord blood cells
- Development stage
- Unknown
- Lead developer
- CIUSSS du Nord-de-l'Île-de-Montréal
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic umbilical cord blood cells (CIUSSS du Nord-de-l'Île-de-Montréal) is an experimental cell therapy being investigated for the treatment of advanced metastatic lung cancer. Developed by the Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'Île-de-Montréal, the therapy involves the infusion of donor-derived immune cells obtained from umbilical cord blood (UCB). This approach is part of the Radio-Immuno-Modulation (RIM) project, which combines the cell infusion with low-dose radiotherapy and the immunomodulatory drug cyclophosphamide. The mechanism relies on the allogeneic cells to trigger a graft-versus-tumor effect, where the donor immune cells recognize and attack the patient's cancer cells. This reaction is intended to be amplified by the immunogenic effects of localized radiotherapy, which can promote the release of tumor antigens and enhance the systemic immune response.
- Other names
- UCB-derived allogeneic immune cellsallogeneic umbilical cord bloodallogeneic immune cells
Beyond the preview
Go deeper on allogeneic umbilical cord blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord blood cells.